Research in the Vestibular NeuroEngineering Lab (VNEL) focuses on restoring inner ear function through “bionic” electrical stimulation, inner ear gene therapy, and enhancing the central nervous system’s ability to learn ways to use sensory input from a damaged inner ear. VNEL research involves basic and applied neurophysiology, biomedical engineering, clinical investigation and population-based epidemiologic studies. We employ techniques including single-unit electrophysiologic recording; histologic examination; 3-D video-oculography and magnetic scleral search coil measurements of eye movements; microCT; micro MRI; and finite element analysis. Our research subjects include computer models, circuits, animals and humans. For more information about VNEL, click here. VNEL is currently recruiting subjects for two first-in-human clinical trials: 1) The MVI Multichannel Vestibular Implant Trial involves implantation of a “bionic” inner ear stimulator intended to partially restore sensation of head movement. Without that sensation, the brain’s image- and posture-stabilizing reflexes fail, so affected individuals suffer difficulty with blurry vision, unsteady walking, chronic dizziness, mental fogginess and a high risk of falling. Based on designs developed and tested successfully in animals over the past the past 15 years at VNEL, the system used in this trial is very similar to a cochlear implant (in fact, future versions could include cochlear electrodes for use in patients who also have hearing loss). Instead of a microphone and cochlear electrodes, it uses gyroscopes to sense head movement, and its electrodes are implanted in the vestibular labyrinth. For more information on the MVI trial, click here. 2) The CGF166 Inner Ear Gene Therapy Trial involves inner ear injection of a genetically engineered DNA sequence intended to restore hearing and balance sensation by creating new sensory cells (called “hair cells”). Performed at VNEL with the support of Novartis and through a collaboration with the University of Kansas and Columbia University, this is the world’s first trial of inner ear gene therapy in human subjects. Individuals with severe or profound hearing loss in both ears are invited to participate. For more information on the CGF166 trial, click here.

The Lima Lab’s research is concentrated on the development and application of imaging and technology to address scientific and clinical problems involving the heart and vascular system. Specifically, our research is focused on developing magnetic resonance imaging (MRI) contrast techniques to investigate microvascular function in patients and experimental animals with myocardial infarction; functional reserve secondary to dobutamine stimulation and myocardial viability assessed by sodium imaging; and cardiac MRI and computed tomography (CT) program development of techniques to characterize atherosclerosis in humans with cardiovascular or cerebrovascular disease. Current projects include: • The Coronary Artery Risk Development in Young Adults (CARDIA) Study • The MESA (Multi-Ethnic Study of Atherosclerosis) Study • The Coronary Artery Evaluation using 64-row Multidetector Computed Tomography Angiography (CORE64) Study Joao Lima, MD, is a professor of medicine, radiology and epidemiology at the Johns Hopkins School of Medicine.

The neuroimaging and Modulation Laboratory (NIMLAB) investigates neural correlates of cognition and behavior using neuroimaging methods such as functional magnetic resonance imaging (fMRI) and neuromodulation techniques such as transcranial magnetic stimulation (TMS). We are looking in depth at the contributions of the cerebellum and cerebro-cerebellar circuits to cognition; the effects of chronic heavy alcohol consumption on cognition and brain activation underlying cognitive function; how aging in humans affects neural systems that are important for associative learning and stimulus awareness; and the integration of transcranial magnetic stimulation with functional MRI.

Lauren Jantzie, professor of pediatrics and vice chair of research for the Department of Pediatrics, received her Ph.D. in neurochemistry from the University of Alberta in 2008. In 2013 she completed her postdoctoral fellowship in the Department of Neurology at Boston Children's Hospital & Harvard Medical School and became faculty at the University of New Mexico. Dr. Jantzie then joined the faculty Departments of Pediatrics (Neonatal-Perinatal Medicine) and Neurology at Johns Hopkins University and the Kennedy Krieger Institute in January 2019.

The Jantzie lab investigates the pathophysiology of encephalopathy of prematurity, and pediatric brain injury common to infants and toddlers. Dr. Jantzie is dedicated to understanding disease processes in the developing brain as a means to identifying new therapeutic strategies and treatment targets for perinatal brain injury. Her lab studies neural substrates of cognition and executive function, inhibitory circuit formation, the role of an abnormal intrauterine environment on brain development, mechanisms of neurorepair and microglial activation and polarization.

Using a diverse array of clinically relevant techniques such as MRI, cognitive assessment, and biomarker discovery, combined with traditional molecular and cellular biology, the Jantzie lab is on the front lines of translational pediatric neuroscience.